Mercola Introduces New Women's Hormonal Health Formula
HOFFMAN ESTATES, Ill., Sept. 29, 2016 /PRNewswire-iReach/ -- An estimated 6,000 women enter menopause every day, with 75 to 85 percent of them experiencing troubling symptoms.
Premenopausal symptoms can be just as bad or worse, yielding discomforts that include breast tenderness, decreased sex drive, fatigue, irregular periods, vaginal dryness, urine leakage, mood swings and more.
Now there is potential relief. Mercola has introduced Lignans with Lycopene, a hormonal balance support supplement that not only provides nutrients to help protect breasts against normal everyday stressors, but is also clinically proven to reduce the frequency and severity of hot flashes.*
Lignans with Lycopene is formulated for total perimenopausal and menopausal health and hormone balance support. Developed for women by women, this patent-pending formula assists the female body in balancing estrogen levels and supports energy and cellular metabolism.*
"If you're a woman over 40 or experience perimenopausal or menopausal symptoms, I believe you'll find that once you try Lignans with Lycopene, you'll wonder how you ever lived without it," said Dr. Joseph Mercola, founder of Mercola.
About Dr. Mercola and Mercola.com:
Dr. Joseph Mercola is a physician and three-time New York Times best-selling author. He was voted the 2009 Ultimate Wellness Game Changer by the Huffington Post and has been featured in several national media outlets including Time magazine, LA Times, CNN, Fox News, ABC News, the Today Show, and The Dr. Oz Show. Dr. Mercola founded his website, Mercola.com, in 1997 and it has since become the world's #1 natural health resource site with over one million subscribers to its natural health e-Newsletter.
*These statements have not been evaluated by the Food and Drug Administration.These products are not intended to diagnose, treat, cure, or prevent any disease.
Media Contact: Dana Gates, Mercola, 847 252 4310 x3512, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com